Chugai Pharmaceutical Advances Innovation and Builds US Recognition in Biopharma on March 20, 2026 biopharma Chugai Collaboration JPM26 open innovation Partnering Office recognition US +
JPM26 Day 3: Sanofi CEO on RSV Scrutiny and Regeneron Dupixent Defense on January 15, 2026 Beyfortus Dupixent JPM26 Paul Hudson Regeneron Respiratory syncytial virus sanofi United States Food and Drug Administration Vaccines +
Novo Nordisk Refocuses on Diabetes and Obesity to Expand GLP-1 Market at JPM26 on January 14, 2026 Diabetes Glucagon-Like Peptide 1 JPM26 Mike Doustdar Novo Nordisk Obesity semaglutide Wegovy pill +
JPM26: Novo Nordisk and Eli Lilly Compete Fiercely in Oral Obesity Treatments on January 14, 2026 eli lilly JPM26 JPMHC Novo Nordisk oral obesity drugs orglipron semaglutide +
JPM26 Live Blog Day 2: GSK Stays the Course Amid Key Biopharma Updates on January 13, 2026 AstraZeneca Day 2 J.P. Morgan Healthcare Conference JPM26 Nordisk SmithKline Beecham +
JPM26: BMS Highlights Early-Stage Bets and Pipeline Progress Amid Late-Stage Pharma Focus on January 13, 2026 Admilparant Burning Mouth Syndrome Camzyos Cobenfy early-stage JPM26 milvexian pipeline pumitamig +
JPM26: Pfizer Fast-Tracks Obesity Programs in Race Against Patent Cliff on January 13, 2026 JPM26 Metsera Obesity Drugs patent cliff Pfizer Phase 3 Clinical Trials +
JPM26 Day 1 Live Blog: Slow Deal Flow Amid Optimism at J.P. Morgan Healthcare Conference on January 13, 2026 AI healthcare Flow J.P. Morgan Healthcare Conference JPM26 M&A +